HILE(SH:603718)2024-07-09 09:35Financial Performance Expectations - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 12 million and 17.5 million yuan, a decrease of 69.7384 million to 64.2384 million yuan compared to the same period last year, representing a year-on-year decline of 85.32% to 78.59%[2]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -17.5 million and -12 million yuan, a decrease of 37.6199 million to 32.1199 million yuan compared to the same period last year, indicating a year-on-year decline of 186.98% to 159.64%[3]. - In the same period last year, the net profit attributable to shareholders was 81.738 million yuan, and the net profit after deducting non-recurring gains and losses was 20.119 million yuan[4]. Reasons for Performance Decline - The decrease in performance is primarily due to the sale of 100% equity in subsidiaries and the liquidation of another subsidiary in 2023, which resulted in over 55 million yuan in investment income last year, creating a high comparative base[5]. - The company implemented an equity incentive plan in 2023, leading to the recognition of corresponding equity incentive expenses, negatively impacting the current period's performance[5]. Investment and Reporting Uncertainties - The financial summary for the company's investment in WuXi Vaccines (Cayman) Inc. (30% ownership) for the first half of 2024 is not yet complete, making related investment gains and losses uncertain[6]. - The data provided in the performance forecast is preliminary and subject to change, with the final financial data to be disclosed in the official half-year report[7].